context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
Absent regulatory or statutory limitations, the target asset allocation for the investment of pension assets in the PSAs for the Europe Plans is 21 % overseas equity, 21 % diversified alternatives, 15 % real estate, 24 % equity-linked liability driven investments, 11 % other liability driven investments and 8 % cash fo... | text | 16 | percentItemType | text: <entity> 16 </entity> <entity type> percentItemType </entity type> <context> Absent regulatory or statutory limitations, the target asset allocation for the investment of pension assets in the PSAs for the Europe Plans is 21 % overseas equity, 21 % diversified alternatives, 15 % real estate, 24 % equity-linked li... | us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage |
Absent regulatory or statutory limitations, the target asset allocation for the investment of pension assets in the PSAs for the Europe Plans is 21 % overseas equity, 21 % diversified alternatives, 15 % real estate, 24 % equity-linked liability driven investments, 11 % other liability driven investments and 8 % cash fo... | text | 35 | percentItemType | text: <entity> 35 </entity> <entity type> percentItemType </entity type> <context> Absent regulatory or statutory limitations, the target asset allocation for the investment of pension assets in the PSAs for the Europe Plans is 21 % overseas equity, 21 % diversified alternatives, 15 % real estate, 24 % equity-linked li... | us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage |
As required by funding regulations or laws, the Company anticipates contributing $ 0.2 million and less than $ 0.2 million to its pension and other postretirement plans, respectively, during 2025. | text | 0.2 | monetaryItemType | text: <entity> 0.2 </entity> <entity type> monetaryItemType </entity type> <context> As required by funding regulations or laws, the Company anticipates contributing $ 0.2 million and less than $ 0.2 million to its pension and other postretirement plans, respectively, during 2025. </context> | us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear |
The Company also sponsors a performance-based, omnibus long-term incentive plan that provides for the grant of a broad range of long-term equity-based and liability-based awards to the Company’s officers and other employees, members of the Board of Directors and any consultants (the “LTIP”). Awards that may be granted ... | text | 0.1 | sharesItemType | text: <entity> 0.1 </entity> <entity type> sharesItemType </entity type> <context> The Company also sponsors a performance-based, omnibus long-term incentive plan that provides for the grant of a broad range of long-term equity-based and liability-based awards to the Company’s officers and other employees, members of t... | us-gaap:CommonStockCapitalSharesReservedForFutureIssuance |
The total fair value of equity-based awards vested during 2024 was $ 7.1 million. No liability-based awards vested during 2024. The total fair values of equity-based awards and liability-based awards vested during 2023 were $ 9.3 million and $ 5.0 million, respectively. | text | 7.1 | monetaryItemType | text: <entity> 7.1 </entity> <entity type> monetaryItemType </entity type> <context> The total fair value of equity-based awards vested during 2024 was $ 7.1 million. No liability-based awards vested during 2024. The total fair values of equity-based awards and liability-based awards vested during 2023 were $ 9.3 milli... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
The total fair value of equity-based awards vested during 2024 was $ 7.1 million. No liability-based awards vested during 2024. The total fair values of equity-based awards and liability-based awards vested during 2023 were $ 9.3 million and $ 5.0 million, respectively. | text | No | monetaryItemType | text: <entity> No </entity> <entity type> monetaryItemType </entity type> <context> The total fair value of equity-based awards vested during 2024 was $ 7.1 million. No liability-based awards vested during 2024. The total fair values of equity-based awards and liability-based awards vested during 2023 were $ 9.3 millio... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
The total fair value of equity-based awards vested during 2024 was $ 7.1 million. No liability-based awards vested during 2024. The total fair values of equity-based awards and liability-based awards vested during 2023 were $ 9.3 million and $ 5.0 million, respectively. | text | 9.3 | monetaryItemType | text: <entity> 9.3 </entity> <entity type> monetaryItemType </entity type> <context> The total fair value of equity-based awards vested during 2024 was $ 7.1 million. No liability-based awards vested during 2024. The total fair values of equity-based awards and liability-based awards vested during 2023 were $ 9.3 milli... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
The total fair value of equity-based awards vested during 2024 was $ 7.1 million. No liability-based awards vested during 2024. The total fair values of equity-based awards and liability-based awards vested during 2023 were $ 9.3 million and $ 5.0 million, respectively. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> The total fair value of equity-based awards vested during 2024 was $ 7.1 million. No liability-based awards vested during 2024. The total fair values of equity-based awards and liability-based awards vested during 2023 were $ 9.3 milli... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
As of December 29, 2024, the total unrecognized compensation cost related to all nonvested equity-based awards was $ 16.9 million. This cost is expected to be recognized over a weighted average period of 1.91 years. As of December 29, 2024, the total unrecognized compensation cost related to all nonvested liability-bas... | text | 16.9 | monetaryItemType | text: <entity> 16.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, the total unrecognized compensation cost related to all nonvested equity-based awards was $ 16.9 million. This cost is expected to be recognized over a weighted average period of 1.91 years. As of December 29,... | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
As of December 29, 2024, the total unrecognized compensation cost related to all nonvested equity-based awards was $ 16.9 million. This cost is expected to be recognized over a weighted average period of 1.91 years. As of December 29, 2024, the total unrecognized compensation cost related to all nonvested liability-bas... | text | immaterial | monetaryItemType | text: <entity> immaterial </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, the total unrecognized compensation cost related to all nonvested equity-based awards was $ 16.9 million. This cost is expected to be recognized over a weighted average period of 1.91 years. As of Decemb... | us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
The Company operates in three reportable segments: U.S., Europe and Mexico. The Company’s reportable segments are identified by a combination of factors, including geographic area, regulatory environment, economic environment and product portfolios. Each reportable segment is managed separately through a local manageme... | text | three | integerItemType | text: <entity> three </entity> <entity type> integerItemType </entity type> <context> The Company operates in three reportable segments: U.S., Europe and Mexico. The Company’s reportable segments are identified by a combination of factors, including geographic area, regulatory environment, economic environment and prod... | us-gaap:NumberOfReportableSegments |
For the year 2024, the U.S. reportable segment had intercompany sales to the Mexico reportable segment of $ 121.6 million. These sales consisted of fresh products, prepared products and grain and are eliminated in our consolidation. | text | 121.6 | monetaryItemType | text: <entity> 121.6 </entity> <entity type> monetaryItemType </entity type> <context> For the year 2024, the U.S. reportable segment had intercompany sales to the Mexico reportable segment of $ 121.6 million. These sales consisted of fresh products, prepared products and grain and are eliminated in our consolidation. ... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
For the year 2023, the U.S. reportable segment had intercompany sales to the Mexico reportable segment of $ 370.1 million. These sales consisted of fresh products, prepared products, eggs and grain and are eliminated in our consolidation.. | text | 370.1 | monetaryItemType | text: <entity> 370.1 </entity> <entity type> monetaryItemType </entity type> <context> For the year 2023, the U.S. reportable segment had intercompany sales to the Mexico reportable segment of $ 370.1 million. These sales consisted of fresh products, prepared products, eggs and grain and are eliminated in our consolida... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
For the year 2022, the U.S. reportable segment had intercompany sales to the Mexico reportable segment of $ 120.9 million. These sales consisted of fresh products, prepared products and grain and are eliminated in our consolidation. For the year 2022, the Europe reportable segment had intercompany sales of eggs to the ... | text | 120.9 | monetaryItemType | text: <entity> 120.9 </entity> <entity type> monetaryItemType </entity type> <context> For the year 2022, the U.S. reportable segment had intercompany sales to the Mexico reportable segment of $ 120.9 million. These sales consisted of fresh products, prepared products and grain and are eliminated in our consolidation. ... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
For the year 2022, the U.S. reportable segment had intercompany sales to the Mexico reportable segment of $ 120.9 million. These sales consisted of fresh products, prepared products and grain and are eliminated in our consolidation. For the year 2022, the Europe reportable segment had intercompany sales of eggs to the ... | text | 5.3 | monetaryItemType | text: <entity> 5.3 </entity> <entity type> monetaryItemType </entity type> <context> For the year 2022, the U.S. reportable segment had intercompany sales to the Mexico reportable segment of $ 120.9 million. These sales consisted of fresh products, prepared products and grain and are eliminated in our consolidation. Fo... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase contracts totaling $ 400.7 million payable in 2025, $ 23.0 million payable in 2026, $ 1... | text | 400.7 | monetaryItemType | text: <entity> 400.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase ... | us-gaap:PurchaseObligationDueInNextTwelveMonths |
The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase contracts totaling $ 400.7 million payable in 2025, $ 23.0 million payable in 2026, $ 1... | text | 23.0 | monetaryItemType | text: <entity> 23.0 </entity> <entity type> monetaryItemType </entity type> <context> The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase c... | us-gaap:PurchaseObligationDueInSecondYear |
The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase contracts totaling $ 400.7 million payable in 2025, $ 23.0 million payable in 2026, $ 1... | text | 1.9 | monetaryItemType | text: <entity> 1.9 </entity> <entity type> monetaryItemType </entity type> <context> The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase co... | us-gaap:PurchaseObligationDueInThirdYear |
The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase contracts totaling $ 400.7 million payable in 2025, $ 23.0 million payable in 2026, $ 1... | text | 1.8 | monetaryItemType | text: <entity> 1.8 </entity> <entity type> monetaryItemType </entity type> <context> The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase co... | us-gaap:PurchaseObligationDueInFourthYear |
The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase contracts totaling $ 400.7 million payable in 2025, $ 23.0 million payable in 2026, $ 1... | text | 10.7 | monetaryItemType | text: <entity> 10.7 </entity> <entity type> monetaryItemType </entity type> <context> The Company will sometimes enter into noncancelable contracts to purchase capital equipment and certain commodities such as corn, soybean meal, wheat and energy. As of December 29, 2024, the Company was party to outstanding purchase c... | us-gaap:PurchaseObligationDueAfterFifthYear |
During 2014 and 2015, the Mexican Tax Administration Service (“SAT”) opened a review of Avícola with regard to tax years 2009 and 2010. In both instances, the SAT claims that controlled company status did not exist for certain subsidiaries because Avícola did not own 50% of the shares in voting rights of Incubadora Hid... | text | 25.9 | monetaryItemType | text: <entity> 25.9 </entity> <entity type> monetaryItemType </entity type> <context> During 2014 and 2015, the Mexican Tax Administration Service (“SAT”) opened a review of Avícola with regard to tax years 2009 and 2010. In both instances, the SAT claims that controlled company status did not exist for certain subsidi... | us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions |
During 2014 and 2015, the Mexican Tax Administration Service (“SAT”) opened a review of Avícola with regard to tax years 2009 and 2010. In both instances, the SAT claims that controlled company status did not exist for certain subsidiaries because Avícola did not own 50% of the shares in voting rights of Incubadora Hid... | text | 14.4 | monetaryItemType | text: <entity> 14.4 </entity> <entity type> monetaryItemType </entity type> <context> During 2014 and 2015, the Mexican Tax Administration Service (“SAT”) opened a review of Avícola with regard to tax years 2009 and 2010. In both instances, the SAT claims that controlled company status did not exist for certain subsidi... | us-gaap:TaxesPayableCurrentAndNoncurrent |
On May 12, 2022, the SAT issued tax assessments against Pilgrim’s Pride, S. de R.L. de C.V. and Provemex Holdings, LLC in connection with PPC’s acquisition of Tyson de México. The Mexican subsidiaries of PPC filed a petition to nullify these assessments. The District Court issued a judgement on January 20, 2025, in whi... | text | 269.5 | monetaryItemType | text: <entity> 269.5 </entity> <entity type> monetaryItemType </entity type> <context> On May 12, 2022, the SAT issued tax assessments against Pilgrim’s Pride, S. de R.L. de C.V. and Provemex Holdings, LLC in connection with PPC’s acquisition of Tyson de México. The Mexican subsidiaries of PPC filed a petition to nulli... | us-gaap:LossContingencyEstimateOfPossibleLoss |
On May 12, 2022, the SAT issued tax assessments against Pilgrim’s Pride, S. de R.L. de C.V. and Provemex Holdings, LLC in connection with PPC’s acquisition of Tyson de México. The Mexican subsidiaries of PPC filed a petition to nullify these assessments. The District Court issued a judgement on January 20, 2025, in whi... | text | No | monetaryItemType | text: <entity> No </entity> <entity type> monetaryItemType </entity type> <context> On May 12, 2022, the SAT issued tax assessments against Pilgrim’s Pride, S. de R.L. de C.V. and Provemex Holdings, LLC in connection with PPC’s acquisition of Tyson de México. The Mexican subsidiaries of PPC filed a petition to nullify ... | us-gaap:LossContingencyLossInPeriod |
In 2019 and 2020, the UK Revenue & Customs Authority (HMRC) opened reviews of the 2017 and 2018 tax returns of Onix Investments UK Ltd in which HMRC evaluated the deductibility of certain interest related expenses incurred by Onix Investments UK Ltd (the “Deductions”). The Deductions total $ 7.9 million for tax year 20... | text | 7.9 | monetaryItemType | text: <entity> 7.9 </entity> <entity type> monetaryItemType </entity type> <context> In 2019 and 2020, the UK Revenue & Customs Authority (HMRC) opened reviews of the 2017 and 2018 tax returns of Onix Investments UK Ltd in which HMRC evaluated the deductibility of certain interest related expenses incurred by Onix Inve... | us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss |
In 2019 and 2020, the UK Revenue & Customs Authority (HMRC) opened reviews of the 2017 and 2018 tax returns of Onix Investments UK Ltd in which HMRC evaluated the deductibility of certain interest related expenses incurred by Onix Investments UK Ltd (the “Deductions”). The Deductions total $ 7.9 million for tax year 20... | text | 32.1 | monetaryItemType | text: <entity> 32.1 </entity> <entity type> monetaryItemType </entity type> <context> In 2019 and 2020, the UK Revenue & Customs Authority (HMRC) opened reviews of the 2017 and 2018 tax returns of Onix Investments UK Ltd in which HMRC evaluated the deductibility of certain interest related expenses incurred by Onix Inv... | us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss |
Case No. 1:16-cv-08637 (the “Broiler Antitrust Litigation”). The complaints seek, among other relief, treble damages for an alleged conspiracy among defendants to reduce output and increase prices of broiler chickens from the period of January 2008 to the present. PPC has entered into agreements to settle all claims ma... | text | 195.5 | monetaryItemType | text: <entity> 195.5 </entity> <entity type> monetaryItemType </entity type> <context> Case No. 1:16-cv-08637 (the “Broiler Antitrust Litigation”). The complaints seek, among other relief, treble damages for an alleged conspiracy among defendants to reduce output and increase prices of broiler chickens from the period ... | us-gaap:LitigationSettlementAmountAwardedToOtherParty |
Case No. 1:16-cv-08637 (the “Broiler Antitrust Litigation”). The complaints seek, among other relief, treble damages for an alleged conspiracy among defendants to reduce output and increase prices of broiler chickens from the period of January 2008 to the present. PPC has entered into agreements to settle all claims ma... | text | 582.5 | monetaryItemType | text: <entity> 582.5 </entity> <entity type> monetaryItemType </entity type> <context> Case No. 1:16-cv-08637 (the “Broiler Antitrust Litigation”). The complaints seek, among other relief, treble damages for an alleged conspiracy among defendants to reduce output and increase prices of broiler chickens from the period ... | us-gaap:LitigationSettlementExpense |
Case No. 1:16-cv-08637 (the “Broiler Antitrust Litigation”). The complaints seek, among other relief, treble damages for an alleged conspiracy among defendants to reduce output and increase prices of broiler chickens from the period of January 2008 to the present. PPC has entered into agreements to settle all claims ma... | text | 45.0 | monetaryItemType | text: <entity> 45.0 </entity> <entity type> monetaryItemType </entity type> <context> Case No. 1:16-cv-08637 (the “Broiler Antitrust Litigation”). The complaints seek, among other relief, treble damages for an alleged conspiracy among defendants to reduce output and increase prices of broiler chickens from the period o... | us-gaap:LitigationSettlementGain |
No.19-cv-02521. The plaintiffs are a putative class of poultry processing plant production and maintenance workers (“Poultry Workers Class”) and allege that the defendants conspired to fix and depress the compensation paid to Poultry Workers Class in violation of the Sherman Antitrust Act. PPC entered into an agreement... | text | 29.0 | monetaryItemType | text: <entity> 29.0 </entity> <entity type> monetaryItemType </entity type> <context> No.19-cv-02521. The plaintiffs are a putative class of poultry processing plant production and maintenance workers (“Poultry Workers Class”) and allege that the defendants conspired to fix and depress the compensation paid to Poultry ... | us-gaap:LitigationSettlementAmountAwardedToOtherParty |
, Case No. CIV-17-033. On June 24, 2024, a settlement was reached in the amount of $ 100.0 million. This settlement was paid on October 28, 2024. We have recognized these settlement expenses within | text | 100.0 | monetaryItemType | text: <entity> 100.0 </entity> <entity type> monetaryItemType </entity type> <context> , Case No. CIV-17-033. On June 24, 2024, a settlement was reached in the amount of $ 100.0 million. This settlement was paid on October 28, 2024. We have recognized these settlement expenses within </context> | us-gaap:LitigationSettlementGain |
, No. 16-CV-02611. The complaint alleges, among other things, that PPC’s SEC filings contained statements that were rendered materially false and misleading. On December 6, 2024, the Company entered into a settlement agreement in principal with the putative class in the amount of $ 41.5 million, which is subject to cou... | text | 41.5 | monetaryItemType | text: <entity> 41.5 </entity> <entity type> monetaryItemType </entity type> <context> , No. 16-CV-02611. The complaint alleges, among other things, that PPC’s SEC filings contained statements that were rendered materially false and misleading. On December 6, 2024, the Company entered into a settlement agreement in prin... | us-gaap:LitigationSettlementExpense |
, 21-2-14174-5), respectively, filed complaints against PPC and others based on allegations similar to those asserted in the Broiler Antitrust Litigation. The State of Washington settlement was paid in the second quarter of 2023 for $ 11.0 million. On June 24, 2024, PPC entered into a settlement with the Attorney Gener... | text | 11.0 | monetaryItemType | text: <entity> 11.0 </entity> <entity type> monetaryItemType </entity type> <context> , 21-2-14174-5), respectively, filed complaints against PPC and others based on allegations similar to those asserted in the Broiler Antitrust Litigation. The State of Washington settlement was paid in the second quarter of 2023 for $... | us-gaap:LossContingencyAccrualAtCarryingValue |
, 21-2-14174-5), respectively, filed complaints against PPC and others based on allegations similar to those asserted in the Broiler Antitrust Litigation. The State of Washington settlement was paid in the second quarter of 2023 for $ 11.0 million. On June 24, 2024, PPC entered into a settlement with the Attorney Gener... | text | 5.2 | monetaryItemType | text: <entity> 5.2 </entity> <entity type> monetaryItemType </entity type> <context> , 21-2-14174-5), respectively, filed complaints against PPC and others based on allegations similar to those asserted in the Broiler Antitrust Litigation. The State of Washington settlement was paid in the second quarter of 2023 for $ ... | us-gaap:LossContingencyAccrualAtCarryingValue |
, 21-2-14174-5), respectively, filed complaints against PPC and others based on allegations similar to those asserted in the Broiler Antitrust Litigation. The State of Washington settlement was paid in the second quarter of 2023 for $ 11.0 million. On June 24, 2024, PPC entered into a settlement with the Attorney Gener... | text | 1.25 | monetaryItemType | text: <entity> 1.25 </entity> <entity type> monetaryItemType </entity type> <context> , 21-2-14174-5), respectively, filed complaints against PPC and others based on allegations similar to those asserted in the Broiler Antitrust Litigation. The State of Washington settlement was paid in the second quarter of 2023 for $... | us-gaap:LitigationSettlementExpense |
As of December 29, 2024, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 0.7 billion and $ 2.9 billion, respectively. As of December 31, 2023, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 1.3 billion and... | text | 0.7 | monetaryItemType | text: <entity> 0.7 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 0.7 billion and $ 2.9 billion, respectively. As of December 31, 2023, the aggregate carrying amount of ne... | us-gaap:AssetsNet |
As of December 29, 2024, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 0.7 billion and $ 2.9 billion, respectively. As of December 31, 2023, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 1.3 billion and... | text | 2.9 | monetaryItemType | text: <entity> 2.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 0.7 billion and $ 2.9 billion, respectively. As of December 31, 2023, the aggregate carrying amount of ne... | us-gaap:AssetsNet |
As of December 29, 2024, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 0.7 billion and $ 2.9 billion, respectively. As of December 31, 2023, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 1.3 billion and... | text | 1.3 | monetaryItemType | text: <entity> 1.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 0.7 billion and $ 2.9 billion, respectively. As of December 31, 2023, the aggregate carrying amount of ne... | us-gaap:AssetsNet |
As of December 29, 2024, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 0.7 billion and $ 2.9 billion, respectively. As of December 31, 2023, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 1.3 billion and... | text | 3.1 | monetaryItemType | text: <entity> 3.1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 29, 2024, the aggregate carrying amount of net assets belonging to our Mexico and Europe reportable segments was $ 0.7 billion and $ 2.9 billion, respectively. As of December 31, 2023, the aggregate carrying amount of ne... | us-gaap:AssetsNet |
Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were approximately $ 1.4 billion in 2023 and $ 1.3 billion in 2022 and 2021. | text | 1.4 | monetaryItemType | text: <entity> 1.4 </entity> <entity type> monetaryItemType </entity type> <context> Advertising and product promotion costs are expensed as incurred. Advertising and product promotion costs are included in Marketing, selling and administrative expenses and were approximately $ 1.4 billion in 2023 and $ 1.3 billion in ... | us-gaap:MarketingAndAdvertisingExpense |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affect... | text | 462 | monetaryItemType | text: <entity> 462 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the... | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affect... | text | 556 | monetaryItemType | text: <entity> 556 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the... | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the period the underlying sales occur. Cumulative catch-up adjustments to revenue affect... | text | 561 | monetaryItemType | text: <entity> 561 </entity> <entity type> monetaryItemType </entity type> <context> Contract assets are primarily estimated future royalties and termination fees not eligible for the licensing exclusion and therefore recognized under ASC 606 and ASC 610. Contract assets are reduced and receivables are increased in the... | us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod |
in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. | text | 358 | monetaryItemType | text: <entity> 358 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. </cont... | us-gaap:Revenues |
in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. | text | 297 | monetaryItemType | text: <entity> 297 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. </cont... | us-gaap:Revenues |
in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. | text | 158 | monetaryItemType | text: <entity> 158 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. </cont... | us-gaap:Revenues |
in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. | text | 109 | monetaryItemType | text: <entity> 109 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. </cont... | us-gaap:CostOfGoodsAndServicesSold |
in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. | text | 49 | monetaryItemType | text: <entity> 49 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. </conte... | us-gaap:CostOfGoodsAndServicesSold |
in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. | text | 42 | monetaryItemType | text: <entity> 42 </entity> <entity type> monetaryItemType </entity type> <context> in the U.S. were $ 358 million, $ 297 million and $ 158 million; and the related profit sharing costs were $ 109 million, $ 49 million and $ 42 million in 2023, 2022 and 2021, respectively. Cost reimbursements were not material. </conte... | us-gaap:CostOfGoodsAndServicesSold |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of estimated cash acquired. Mirati stockholders will also receive one non-tradeable contingent value right for each share of Mi... | text | 58.00 | perShareItemType | text: <entity> 58.00 </entity> <entity type> perShareItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of estimated cash acquired. Mirati stock... | us-gaap:BusinessAcquisitionSharePrice |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of estimated cash acquired. Mirati stockholders will also receive one non-tradeable contingent value right for each share of Mi... | text | 4.8 | monetaryItemType | text: <entity> 4.8 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of estimated cash acquired. Mirati stockho... | us-gaap:PaymentsToAcquireBusinessesGross |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of estimated cash acquired. Mirati stockholders will also receive one non-tradeable contingent value right for each share of Mi... | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of estimated cash acquired. Mirati stockho... | us-gaap:BusinessCombinationConsiderationTransferred1 |
BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of estimated cash acquired. Mirati stockholders will also receive one non-tradeable contingent value right for each share of Mi... | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> BMS acquired all of the issued and outstanding shares of Mirati's common stock for $ 58.00 per share in an all-cash transaction for a total consideration of $ 4.8 billion or $ 4.1 billion, net of estimated cash acquired. Mirati stockho... | us-gaap:BusinessCombinationContingentConsiderationLiability |
BMS will acquire all of the issued and outstanding shares of Karuna's common stock for $ 330.00 per share in an all-cash transaction for a total consideration of $ 14.0 billion. The accounting treatment as a business combination or asset acquisition will be determined in the period the transaction closes. The transacti... | text | 14.0 | monetaryItemType | text: <entity> 14.0 </entity> <entity type> monetaryItemType </entity type> <context> BMS will acquire all of the issued and outstanding shares of Karuna's common stock for $ 330.00 per share in an all-cash transaction for a total consideration of $ 14.0 billion. The accounting treatment as a business combination or as... | us-gaap:PaymentsToAcquireBusinessesGross |
BMS will acquire all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for a total consideration of $ 4.1 billion. The transaction is expected to be accounted for as a business combination and is anticipated to close in the first half of 2024, subject to fu... | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> BMS will acquire all of the issued and outstanding shares of RayzeBio's common stock for $ 62.50 per share in an all-cash transaction for a total consideration of $ 4.1 billion. The transaction is expected to be accounted for as a busi... | us-gaap:PaymentsToAcquireBusinessesGross |
In November 2023, BMS acquired the rights to Orum's ORM-6151 program, which is in preclinical development. ORM-6151 is a anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase I for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes. The consi... | text | 80 | monetaryItemType | text: <entity> 80 </entity> <entity type> monetaryItemType </entity type> <context> In November 2023, BMS acquired the rights to Orum's ORM-6151 program, which is in preclinical development. ORM-6151 is a anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase I for the treatment of pa... | us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration |
In 2022, BMS acquired Turning Point for $ 4.1 billion of cash (or $ 3.3 billion net of cash acquired). Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS... | text | 4.1 | monetaryItemType | text: <entity> 4.1 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS acquired Turning Point for $ 4.1 billion of cash (or $ 3.3 billion net of cash acquired). Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the co... | us-gaap:PaymentsToAcquireBusinessesGross |
In 2022, BMS acquired Turning Point for $ 4.1 billion of cash (or $ 3.3 billion net of cash acquired). Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the common mutations and alterations that drive cancer growth. The acquisition provided BMS... | text | 3.3 | monetaryItemType | text: <entity> 3.3 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS acquired Turning Point for $ 4.1 billion of cash (or $ 3.3 billion net of cash acquired). Turning Point was a clinical-stage precision oncology company with a pipeline of investigational medicines designed to target the co... | us-gaap:BusinessCombinationConsiderationTransferred1 |
(a) Included unvested equity awards of $ 73 million expensed in Marketing, selling, and administrative and $ 80 million expensed in Research and development in 2022. | text | 73 | monetaryItemType | text: <entity> 73 </entity> <entity type> monetaryItemType </entity type> <context> (a) Included unvested equity awards of $ 73 million expensed in Marketing, selling, and administrative and $ 80 million expensed in Research and development in 2022. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
(a) Included unvested equity awards of $ 73 million expensed in Marketing, selling, and administrative and $ 80 million expensed in Research and development in 2022. | text | 80 | monetaryItemType | text: <entity> 80 </entity> <entity type> monetaryItemType </entity type> <context> (a) Included unvested equity awards of $ 73 million expensed in Marketing, selling, and administrative and $ 80 million expensed in Research and development in 2022. </context> | us-gaap:PaymentsToAcquireBusinessesGross |
(a) Intangible assets included $ 2.8 billion of IPRD allocated to repotrectinib ( | text | 2.8 | monetaryItemType | text: <entity> 2.8 </entity> <entity type> monetaryItemType </entity type> <context> (a) Intangible assets included $ 2.8 billion of IPRD allocated to repotrectinib ( </context> | us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets |
In 2022, BMS agreed to sell its manufacturing facility in Syracuse, New York to LOTTE Corporation and accounted for the business as held-for-sale, which resulted in a $ 63 million impairment charge recorded to Cost of products sold. Assets and liabilities reclassified to held-for-sale were included within Other current... | text | 63 | monetaryItemType | text: <entity> 63 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS agreed to sell its manufacturing facility in Syracuse, New York to LOTTE Corporation and accounted for the business as held-for-sale, which resulted in a $ 63 million impairment charge recorded to Cost of products sold. Ass... | us-gaap:AssetImpairmentCharges |
In 2022, BMS agreed to sell its manufacturing facility in Syracuse, New York to LOTTE Corporation and accounted for the business as held-for-sale, which resulted in a $ 63 million impairment charge recorded to Cost of products sold. Assets and liabilities reclassified to held-for-sale were included within Other current... | text | 172 | monetaryItemType | text: <entity> 172 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS agreed to sell its manufacturing facility in Syracuse, New York to LOTTE Corporation and accounted for the business as held-for-sale, which resulted in a $ 63 million impairment charge recorded to Cost of products sold. As... | us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent |
In 2022, BMS agreed to sell its manufacturing facility in Syracuse, New York to LOTTE Corporation and accounted for the business as held-for-sale, which resulted in a $ 63 million impairment charge recorded to Cost of products sold. Assets and liabilities reclassified to held-for-sale were included within Other current... | text | 20 | monetaryItemType | text: <entity> 20 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS agreed to sell its manufacturing facility in Syracuse, New York to LOTTE Corporation and accounted for the business as held-for-sale, which resulted in a $ 63 million impairment charge recorded to Cost of products sold. Ass... | us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent |
In 2022, BMS agreed to sell its manufacturing facility in Syracuse, New York to LOTTE Corporation and accounted for the business as held-for-sale, which resulted in a $ 63 million impairment charge recorded to Cost of products sold. Assets and liabilities reclassified to held-for-sale were included within Other current... | text | 159 | monetaryItemType | text: <entity> 159 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS agreed to sell its manufacturing facility in Syracuse, New York to LOTTE Corporation and accounted for the business as held-for-sale, which resulted in a $ 63 million impairment charge recorded to Cost of products sold. As... | us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration |
effective as of December 31, 2023, subject to BeiGene’s right to continue to sell all remaining inventory beyond that date. In consideration for the above, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock held under a share subscription agreement back to BeiGene resulting in $ 322 million ... | text | 322 | monetaryItemType | text: <entity> 322 </entity> <entity type> monetaryItemType </entity type> <context> effective as of December 31, 2023, subject to BeiGene’s right to continue to sell all remaining inventory beyond that date. In consideration for the above, BMS agreed to transfer 23.3 million of BeiGene ordinary shares of common stock ... | us-gaap:LitigationSettlementExpense |
In 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations, as further described in "—Note 20. Legal Proceedings and Contingencies." AstraZeneca will pay an aggregate of $ 560 million to BMS in four payment... | text | 560 | monetaryItemType | text: <entity> 560 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations, as further described in "—Note 20. Legal Proceedings and Cont... | us-gaap:LitigationSettlementAmountAwardedFromOtherParty |
In 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations, as further described in "—Note 20. Legal Proceedings and Contingencies." AstraZeneca will pay an aggregate of $ 560 million to BMS in four payment... | text | 418 | monetaryItemType | text: <entity> 418 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations, as further described in "—Note 20. Legal Proceedings and Cont... | us-gaap:ProceedsFromLegalSettlements |
In 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations, as further described in "—Note 20. Legal Proceedings and Contingencies." AstraZeneca will pay an aggregate of $ 560 million to BMS in four payment... | text | 384 | monetaryItemType | text: <entity> 384 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS entered into an agreement with AstraZeneca to settle all outstanding claims between the parties in the CTLA-4 litigation and the two PD-L1 antibody litigations, as further described in "—Note 20. Legal Proceedings and Cont... | us-gaap:LitigationSettlementAmountAwardedFromOtherParty |
In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory appro... | text | 40 | monetaryItemType | text: <entity> 40 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provide... | us-gaap:ProceedsFromLegalSettlements |
In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provides for BMS to receive additional amounts for contingent development, regulatory appro... | text | 400 | monetaryItemType | text: <entity> 400 </entity> <entity type> monetaryItemType </entity type> <context> In 2022, BMS and Nimbus entered into a settlement resolving all legal claims and business interests pertaining to Nimbus' TYK2 inhibitor resulting in $ 40 million of income included in Other (income)/expense. The settlement also provid... | us-gaap:ProceedsFromLegalSettlements |
Contingent consideration in 2021 included $ 513 million of fair value adjustments resulting from the change in the traded price of contingent value rights issued with the Celgene acquisition. The contractual obligation to pay the contingent value rights terminated in January 2021 because the FDA did not approve liso-ce... | text | 513 | monetaryItemType | text: <entity> 513 </entity> <entity type> monetaryItemType </entity type> <context> Contingent consideration in 2021 included $ 513 million of fair value adjustments resulting from the change in the traded price of contingent value rights issued with the Celgene acquisition. The contractual obligation to pay the conti... | us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 |
In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to ensure its operating model supports and is appropriately aligned with the Company’s str... | text | 1.0 | monetaryItemType | text: <entity> 1.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, BMS commenced a restructuring plan to accelerate the delivery of medicines to patients by evolving and streamlining its enterprise operating model in key areas, such as R&D, manufacturing, commercial and other functions, to en... | us-gaap:RestructuringAndRelatedCostExpectedCost1 |
Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisition of Celgene (2019), MyoKardia (2020) and Turning Point (2022). As part of these plans, the Company expects to incur charges of approximately $ 3.9 billion. Cumulative charg... | text | 3.9 | monetaryItemType | text: <entity> 3.9 </entity> <entity type> monetaryItemType </entity type> <context> Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisition of Celgene (2019), MyoKardia (2020) and Turning Point (2022). As part of these plans, ... | us-gaap:RestructuringAndRelatedCostExpectedCost1 |
Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisition of Celgene (2019), MyoKardia (2020) and Turning Point (2022). As part of these plans, the Company expects to incur charges of approximately $ 3.9 billion. Cumulative charg... | text | 3.6 | monetaryItemType | text: <entity> 3.6 </entity> <entity type> monetaryItemType </entity type> <context> Restructuring and integration plans were initiated to realize expected cost synergies resulting from cost savings and avoidance from the acquisition of Celgene (2019), MyoKardia (2020) and Turning Point (2022). As part of these plans, ... | us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 |
(a) Includes reductions to the liability resulting from changes in estimates of $ 9 million in 2023 and $ 7 million in 2022. | text | 9 | monetaryItemType | text: <entity> 9 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes reductions to the liability resulting from changes in estimates of $ 9 million in 2023 and $ 7 million in 2022. </context> | us-gaap:RestructuringReserveAccrualAdjustment1 |
(a) Includes reductions to the liability resulting from changes in estimates of $ 9 million in 2023 and $ 7 million in 2022. | text | 7 | monetaryItemType | text: <entity> 7 </entity> <entity type> monetaryItemType </entity type> <context> (a) Includes reductions to the liability resulting from changes in estimates of $ 9 million in 2023 and $ 7 million in 2022. </context> | us-gaap:RestructuringReserveAccrualAdjustment1 |
GILTI, net of foreign derived intangible income deduction includes a benefit of approximately $ 325 million due to the revised 2023 guidance regarding the deductibility of certain research and development expenses. | text | 325 | monetaryItemType | text: <entity> 325 </entity> <entity type> monetaryItemType </entity type> <context> GILTI, net of foreign derived intangible income deduction includes a benefit of approximately $ 325 million due to the revised 2023 guidance regarding the deductibility of certain research and development expenses. </context> | us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment |
U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 89 million in 2023 and $ 522 million in 2022. | text | 89 | monetaryItemType | text: <entity> 89 </entity> <entity type> monetaryItemType </entity type> <context> U.S. Federal, state and foreign contingent tax matters include tax benefits related to lapse of statute and effectively settled contingent tax matters of $ 89 million in 2023 and $ 522 million in 2022. </context> | us-gaap:IncomeTaxReconciliationTaxSettlements |
Puerto Rico imposed an excise tax on the gross company purchase price of goods sold from BMS’s manufacturer in Puerto Rico. The excise tax was recognized in Cost of products sold when the intra-entity sale occurred. For U.S. income tax purposes, the excise tax was not deductible but resulted in foreign tax credits that... | text | 10.5 | percentItemType | text: <entity> 10.5 </entity> <entity type> percentItemType </entity type> <context> Puerto Rico imposed an excise tax on the gross company purchase price of goods sold from BMS’s manufacturer in Puerto Rico. The excise tax was recognized in Cost of products sold when the intra-entity sale occurred. For U.S. income tax... | us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential |
The U.S. Federal net operating loss carryforwards were $ 420 million at December 31, 2023. These carryforwards were acquired as a result of certain acquisitions and are subject to limitations under Section 382 of the Internal Revenue Code. The net operating loss carryforwards expire in varying amounts beginning in 2024... | text | 420 | monetaryItemType | text: <entity> 420 </entity> <entity type> monetaryItemType </entity type> <context> The U.S. Federal net operating loss carryforwards were $ 420 million at December 31, 2023. These carryforwards were acquired as a result of certain acquisitions and are subject to limitations under Section 382 of the Internal Revenue C... | us-gaap:OperatingLossCarryforwards |
At December 31, 2023, a valuation allowance of $ 764 million exists for the following items: $ 319 million primarily for foreign net operating loss and tax credit carryforwards, $ 303 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 142 million for U.S. Federal defer... | text | 764 | monetaryItemType | text: <entity> 764 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2023, a valuation allowance of $ 764 million exists for the following items: $ 319 million primarily for foreign net operating loss and tax credit carryforwards, $ 303 million for state deferred tax assets including net... | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2023, a valuation allowance of $ 764 million exists for the following items: $ 319 million primarily for foreign net operating loss and tax credit carryforwards, $ 303 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 142 million for U.S. Federal defer... | text | 319 | monetaryItemType | text: <entity> 319 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2023, a valuation allowance of $ 764 million exists for the following items: $ 319 million primarily for foreign net operating loss and tax credit carryforwards, $ 303 million for state deferred tax assets including net... | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2023, a valuation allowance of $ 764 million exists for the following items: $ 319 million primarily for foreign net operating loss and tax credit carryforwards, $ 303 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 142 million for U.S. Federal defer... | text | 303 | monetaryItemType | text: <entity> 303 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2023, a valuation allowance of $ 764 million exists for the following items: $ 319 million primarily for foreign net operating loss and tax credit carryforwards, $ 303 million for state deferred tax assets including net... | us-gaap:DeferredTaxAssetsValuationAllowance |
At December 31, 2023, a valuation allowance of $ 764 million exists for the following items: $ 319 million primarily for foreign net operating loss and tax credit carryforwards, $ 303 million for state deferred tax assets including net operating loss and tax credit carryforwards and $ 142 million for U.S. Federal defer... | text | 142 | monetaryItemType | text: <entity> 142 </entity> <entity type> monetaryItemType </entity type> <context> At December 31, 2023, a valuation allowance of $ 764 million exists for the following items: $ 319 million primarily for foreign net operating loss and tax credit carryforwards, $ 303 million for state deferred tax assets including net... | us-gaap:DeferredTaxAssetsValuationAllowance |
Income tax payments were $ 4.3 billion in 2023, $ 5.4 billion in 2022 and $ 3.5 billion in 2021. | text | 4.3 | monetaryItemType | text: <entity> 4.3 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 4.3 billion in 2023, $ 5.4 billion in 2022 and $ 3.5 billion in 2021. </context> | us-gaap:IncomeTaxesPaidNet |
Income tax payments were $ 4.3 billion in 2023, $ 5.4 billion in 2022 and $ 3.5 billion in 2021. | text | 5.4 | monetaryItemType | text: <entity> 5.4 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 4.3 billion in 2023, $ 5.4 billion in 2022 and $ 3.5 billion in 2021. </context> | us-gaap:IncomeTaxesPaidNet |
Income tax payments were $ 4.3 billion in 2023, $ 5.4 billion in 2022 and $ 3.5 billion in 2021. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> Income tax payments were $ 4.3 billion in 2023, $ 5.4 billion in 2022 and $ 3.5 billion in 2021. </context> | us-gaap:IncomeTaxesPaidNet |
It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2023 could decrease in the range of approximately $ 100 million to $ 140 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benef... | text | 100 | monetaryItemType | text: <entity> 100 </entity> <entity type> monetaryItemType </entity type> <context> It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2023 could decrease in the range of approximately $ 100 million to $ 140 million in the next twelve months as a result of the settlement ... | us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible |
It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2023 could decrease in the range of approximately $ 100 million to $ 140 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benef... | text | 140 | monetaryItemType | text: <entity> 140 </entity> <entity type> monetaryItemType </entity type> <context> It is also reasonably possible that the total amount of unrecognized tax benefits at December 31, 2023 could decrease in the range of approximately $ 100 million to $ 140 million in the next twelve months as a result of the settlement ... | us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible |
Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without readily determinable fair values still held as of December 31, 2023 were $ 190 million and $ 75 million, respectively. | text | 190 | monetaryItemType | text: <entity> 190 </entity> <entity type> monetaryItemType </entity type> <context> Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without readily determinable fair values still held as of December 31, 2023 were $ 190 million a... | us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount |
Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without readily determinable fair values still held as of December 31, 2023 were $ 190 million and $ 75 million, respectively. | text | 75 | monetaryItemType | text: <entity> 75 </entity> <entity type> monetaryItemType </entity type> <context> Cumulative upwards adjustments and cumulative impairments and downward adjustments based on observable price changes in equity investments without readily determinable fair values still held as of December 31, 2023 were $ 190 million an... | us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount |
BMS enters into foreign currency forward and purchased local currency put option contracts (foreign exchange contracts) to hedge certain forecasted intercompany inventory sales and certain other foreign currency transactions. The objective of these foreign exchange contracts is to reduce variability caused by changes i... | text | 4 | monetaryItemType | text: <entity> 4 </entity> <entity type> monetaryItemType </entity type> <context> BMS enters into foreign currency forward and purchased local currency put option contracts (foreign exchange contracts) to hedge certain forecasted intercompany inventory sales and certain other foreign currency transactions. The objecti... | us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths |
BMS enters into foreign currency forward and purchased local currency put option contracts (foreign exchange contracts) to hedge certain forecasted intercompany inventory sales and certain other foreign currency transactions. The objective of these foreign exchange contracts is to reduce variability caused by changes i... | text | 4.4 | monetaryItemType | text: <entity> 4.4 </entity> <entity type> monetaryItemType </entity type> <context> BMS enters into foreign currency forward and purchased local currency put option contracts (foreign exchange contracts) to hedge certain forecasted intercompany inventory sales and certain other foreign currency transactions. The objec... | us-gaap:DerivativeNotionalAmount |
BMS enters into foreign currency forward and purchased local currency put option contracts (foreign exchange contracts) to hedge certain forecasted intercompany inventory sales and certain other foreign currency transactions. The objective of these foreign exchange contracts is to reduce variability caused by changes i... | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> BMS enters into foreign currency forward and purchased local currency put option contracts (foreign exchange contracts) to hedge certain forecasted intercompany inventory sales and certain other foreign currency transactions. The objec... | us-gaap:DerivativeNotionalAmount |
BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of the long-term debt to U.S. dollars from euros and are designated as cash flow hedges. ... | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> BMS also enters into cross-currency swap contracts to hedge exposure to foreign currency exchange rate risk associated with its long-term debt denominated in euros. These contracts convert interest payments and principal repayment of t... | us-gaap:DerivativeNotionalAmount |
Cross-currency swap contracts and foreign currency forward contracts of $ 962 million as of December 31, 2023 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offse... | text | 962 | monetaryItemType | text: <entity> 962 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 962 million as of December 31, 2023 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes ar... | us-gaap:DerivativeNotionalAmount |
Cross-currency swap contracts and foreign currency forward contracts of $ 962 million as of December 31, 2023 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offse... | text | 524 | monetaryItemType | text: <entity> 524 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 962 million as of December 31, 2023 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes ar... | us-gaap:DerivativeNotionalAmount |
Cross-currency swap contracts and foreign currency forward contracts of $ 962 million as of December 31, 2023 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of AOCL with a related offse... | text | 438 | monetaryItemType | text: <entity> 438 </entity> <entity type> monetaryItemType </entity type> <context> Cross-currency swap contracts and foreign currency forward contracts of $ 962 million as of December 31, 2023 are designated to hedge currency exposure of BMS's net investment in its foreign subsidiaries. Contract fair value changes ar... | us-gaap:DerivativeNotionalAmount |
In 2023, the Company de-designated its remaining net investment hedge in debt denominated in euros of € 375 million, and the amount represents the effective portion of foreign exchange loss on the remeasurement of the debt. | text | 375 | monetaryItemType | text: <entity> 375 </entity> <entity type> monetaryItemType </entity type> <context> In 2023, the Company de-designated its remaining net investment hedge in debt denominated in euros of € 375 million, and the amount represents the effective portion of foreign exchange loss on the remeasurement of the debt. </context> | us-gaap:DebtInstrumentFaceAmount |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.